CN107213171A - A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder - Google Patents
A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder Download PDFInfo
- Publication number
- CN107213171A CN107213171A CN201710450413.3A CN201710450413A CN107213171A CN 107213171 A CN107213171 A CN 107213171A CN 201710450413 A CN201710450413 A CN 201710450413A CN 107213171 A CN107213171 A CN 107213171A
- Authority
- CN
- China
- Prior art keywords
- freeze
- bacteriophagic bdellovibrio
- dried powder
- bdellovibrio
- bacteriophagic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Abstract
The invention provides a kind of production method of high, the powdered freeze dried preparation of bacteriophagic Bdellovibrio of survival rate, including according to bacteriophagic Bdellovibrio conventional culture methods obtain bacterium solution, or by harmful host separate after bacteriophagic Bdellovibrio bacteria suspension；Prepare protection agent solution；By after after the freeze-drying of lyophilized mixed liquor, vacuumize repeatedly, rush inert gas so that preparation ultimately becomes powdered；Above-mentioned bacteriophagic Bdellovibrio freeze-dried powder preparation is packed under vacuum or under conditions of filling inert gas, bacteriophagic Bdellovibrio freeze-dried powder preparation finished product is made.By the compounding of a variety of freeze drying protectants, the lyophilized survival rate of Bdellovibrio is improved, and the character of bacteriophagic Bdellovibrio freeze-dried powder preparation is powdered, is conducive to the scattered and compounding of freeze-dried powder preparation.
Description
Technical field
The invention belongs to field of biological, and in particular to a kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder.
Background technology
Animal bacteria disease is prevented and treated using biotechnology to be widely used by people.Particularly leech arc
The application of bacterium is more and more paid close attention to by people.Due to bacteriophagic Bdellovibrio major cleavage Gram-negative bacteria, such as Escherichia coli,
The gram negative pathogenic bacterias such as salmonella, Aeromonas hydrophila, vibrios, and it is harmless to humans and animals, compared to traditional thing
Physicochemical antibiotic, which eliminates pathogenic bacteria, obvious advantage.
The drawbacks of traditional physical chemistry antibiotic has obvious on harmful levels of pathogens is eliminated, physical method is caused to various
The elimination effect of germ can be only applied to a certain link of association area, it is impossible to realize the covering in whole field.It is chemical and anti-
Rear pathogenic bacteria easily form resistance to raw element method by long-term use, using effect are reduced, while also destruction inhibits beneficial bacterium
, there is potential environmental hazard, can not finally efficiently control, eliminate pathogenic bacteria in group.So, bacteriophagic Bdellovibrio is gradually wide
It is general to be applied to water body treating in aquaculture, the prevention and treatment of vibrios in fish shrimp crab, and chicken and duck class intestines problem control.
Harsh to environmental requirement because bacteriophagic Bdellovibrio does not generate gemma, its environment temperature survived is 4~45 DEG C, existing
It is liquid bio preparation in the biological agent of the bacteriophagic Bdellovibrio used.It is continuous with itself bacterium due in liquid formulation
Growth and breeding, can cause the metabolism product in liquid mechanism constantly to accumulate, pH value is gradually changed, and miscellaneous bacteria also can increasingly increase
Value.Meanwhile, when environment temperature is higher than 25 DEG C, the viable count of the bacteriophagic Bdellovibrio in liquid formulation is decayed rapidly, and its curative effect is also fast
Speed declines, therefore, and the shelf-life of liquid preparation at normal temperatures only has three, four months or so, has had a strong impact on the biological products
Popularization and application.Therefore, people start by Bdellovibrio freeze to be prepared into freeze-dried powder in order to long-term preservation.
Existing patent (application number 99112389.1) mixes bacteriophagic Bdellovibrio (viable bacteria body) with the viable bacteria body of streptococcus fecalis
Bacteria suspension is prepared into, is mixed by a certain percentage with protective agent by the bacteria suspension prepared, its protective agent is sucrose and gelatin group
Conjunction or the combination of sucrose and skimmed milk power.Freeze-dried powder is obtained after mixed liquor is carried out into pre-freeze, distillation, parsing again, its Bdellovibrio
Lose nearly an order of magnitude after freeze drying, survival rate is between 50~70%.The protective agent composition of the patent is simple, and freeze-dried powder is bitten
Bacterium Bdellovibrio survival rate is not high, is 50~70%.Meanwhile, specific lyophilized technique is not disclosed, lacks specific Operating Guideline.Most
Host is streptococcus fecalis afterwards, and host type is single, general for the preservation effect of Bdellovibrio.
Existing patent (application number 00112230.4) elaborates the freeze-drying process that a kind of host is dead host.Phagocytosis leech
Bacterium solution is made according to inactivation host's cultural method in vibrios, obtains bacteriophagic Bdellovibrio aqua.By bacteriophagic Bdellovibrio aqua and stabilizer
Mixing, obtains lyophilized mixed liquor, is freeze-dried.Wherein its freeze drying protectant is skimmed milk power sucrose stabilizer, and freezing is dry
Dry temperature is -50 DEG C~37 DEG C.Pre-freezing temperature is -20~-50 DEG C.But, bacteriophagic Bdellovibrio host is lethal Fu Shi will
Hayes dysentery bacillus either Escherichia coli.Using the Bdellovibrio of host's culture of inactivation, its infection ability is weaker, while using chlorine
There is potential environmental hazard in imitative progress inactivation, while host, which is Fu Shi Hayes dysentery bacillus or Escherichia coli, is respectively provided with stronger cause
Characteristic of disease, if inactivation does not have powerful destructiveness thoroughly to environment.Meanwhile, freeze drying protectant component is simple, is not carried in patent
And lyophilized survival rate is how many, effect is unknown, there is obvious uncertainty, lacks referential.
The content of the invention
In view of this, it is an object of the invention to provide a kind of high, the powdered freeze dried preparation of bacteriophagic Bdellovibrio of survival rate
Production method, comprise the following steps：
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension：Bacterium solution, Su Zhuwei are obtained according to the conventional culture methods of bacteriophagic Bdellovibrio
The Gram-negative bacteria of no pathogenicity, or by harmful host separate after bacteriophagic Bdellovibrio bacteria suspension；
B. the preparation of agent solution is protected：The bacteriophagic Bdellovibrio bacteria suspension of agent solution and the step a will be protected according to 1：1 body
Product ratio mixing, obtained bacteriophagic Bdellovibrio mixed liquor to be freezed；
C. the freeze-drying of mixed liquor to be freezed：
Bacteriophagic Bdellovibrio mixed liquor to be freezed is positioned in vacuum freeze dryer and carries out vacuum freeze drying, is obtained
Obtain freeze dried preparation of bacteriophagic Bdellovibrio；
D. block lyophilized formulations are vacuumized repeatedly, rushes inert gas so that preparation ultimately becomes powdered；
E. above-mentioned bacteriophagic Bdellovibrio freeze-dried powder preparation is carried out under vacuum or under conditions of filling inert gas
Pack, bacteriophagic Bdellovibrio freeze-dried powder preparation finished product is made.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, the step a no pathogenicities
Host is：Bacillus subtilis, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, lactobacillus bulgaricus, lactic acid sheet
Coccus, streptococcus lactis, VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactobacillus lactis, plant breast
Bacillus or the one or more of Pediococcus pentosaceus.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, the phagocytosis leech of the step a
Vibrios bacteria suspension is the bacteriophagic Bdellovibrio bacteria suspension of the Gram-negative bacteria containing no pathogenicity.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, the no pathogenicity leather is blue
Family name's negative bacterium source is host in itself or by manually adding acquisition, the Gram-negative of final bacteriophagic Bdellovibrio and no pathogenicity
Bacterium quantitative proportion is：1:10~1：100.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, described no pathogenicity
Gram-negative bacteria be bacillus subtilis, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, lactobacillus bulgaricus,
Pediococcus acidilactici, streptococcus lactis, VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactobacillus lactis,
Lactobacillus plantarum or the one or more of Pediococcus pentosaceus.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, the protective agent of the step b
Solution compound method is to dissolve skimmed milk power, beta-schardinger dextrin, trehalose, mannitol, lucid asparagus respectively using the purified water of sterilizing
Propylhomoserin so that its final mass concentration is respectively 2%~10%, 2%~10%, 2%~4%, 2%~6%, 2%~8%.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, phagocytosis leech in the step c
The mixed volume ratio of vibrios bacteria suspension and protection agent solution is 1:1~1:2.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, the step d freezes to described
The parameter of dry preparation processing is that pre-freezing temperature is -30~-20 DEG C, and the pre-freeze time is 2~5 hours, freezing dry process temperature model
Enclose for -15~37 DEG C, vacuum range is 0.05 millibar~0.2 millibar, freeze-drying time is 24~48 hours.
Preferably, in the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation of the present invention, to described in the step d
The character of block lyophilized formulations is：Loose block structure, water content is 1~5%, and survival rate is more than 85%.
Another object of the present invention is to provide the bacteriophagic Bdellovibrio freeze-dried powder preparation of above method acquisition.
Compared with prior art, the present invention has advantages below to the present invention：
1), the present invention improves the lyophilized survival rate of Bdellovibrio by the compounding of a variety of freeze drying protectants.
2), secondly, the character of bacteriophagic Bdellovibrio freeze-dried powder preparation of the invention is powdered, is conducive to freeze-dried powder preparation
It is scattered, i.e.,：According to actual needs, bacteriophagic Bdellovibrio powder preparation dilution is carried out by other powder, having reached preferably makes
Use effect.
3) finally, by the host added with beneficial ecological environment, bacteriophagic Bdellovibrio Bdellovibrio in freeze-dried powder is not only increased
The speed and stability of recovery.Meanwhile, positive effect is also played in actual production application, not only without potential
Environmental hazard, and also help the protection of environment.
Embodiment
In one embodiment of the invention there is provided the production method of freeze dried preparation of bacteriophagic Bdellovibrio, including following step
Suddenly：
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension：Bacterium solution, Su Zhuwei are obtained according to the conventional culture methods of bacteriophagic Bdellovibrio
The Gram-negative bacteria of no pathogenicity, or by harmful host separate after bacteriophagic Bdellovibrio bacteria suspension；
B. the preparation of agent solution is protected：The bacteriophagic Bdellovibrio bacteria suspension of agent solution and the step a will be protected according to 1：1 body
Product ratio mixing, obtained bacteriophagic Bdellovibrio mixed liquor to be freezed；
C. the freeze-drying of mixed liquor to be freezed：
Bacteriophagic Bdellovibrio mixed liquor to be freezed is positioned in vacuum freeze dryer and carries out vacuum freeze drying, is obtained
Obtain freeze dried preparation of bacteriophagic Bdellovibrio；
D. block lyophilized formulations are vacuumized repeatedly, rushes inert gas so that preparation ultimately becomes powdered；
E. above-mentioned bacteriophagic Bdellovibrio freeze-dried powder preparation is carried out under vacuum or under conditions of filling inert gas
Pack, bacteriophagic Bdellovibrio freeze-dried powder preparation finished product is made.
Preferably, in another embodiment of the present invention, the no pathogenicity host in the step a is：Withered grass gemma
Bacillus, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, lactobacillus bulgaricus, Pediococcus acidilactici, streptococcus lactis,
VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactobacillus lactis, Lactobacillus plantarum or Pediococcus pentosaceus
One or more.
Preferably, in another embodiment of the present invention, the bacteriophagic Bdellovibrio bacteria suspension of the step a is containing whetheing there is cause
The bacteriophagic Bdellovibrio bacteria suspension of the Gram-negative bacteria of characteristic of disease.
Preferably, in another embodiment of the present invention, the no pathogenicity derived from gram-negative bacteria is host's sheet
Body or by manually adding acquisition, the Gram-negative bacteria quantitative proportion of final bacteriophagic Bdellovibrio and no pathogenicity is：1:10~
1：100.
Preferably, in another embodiment of the present invention, the Gram-negative bacteria of described no pathogenicity is withered grass bud
Spore bacillus, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, lactobacillus bulgaricus, Pediococcus acidilactici, nisin
Bacterium, VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactobacillus lactis, Lactobacillus plantarum or pentose piece
The one or more of coccus.
Preferably, in another embodiment of the present invention, the protection agent solution compound method of the step b is to use
The purified water of sterilizing dissolves skimmed milk power, beta-schardinger dextrin, trehalose, mannitol, asparatate respectively so that its final mass
Concentration is respectively 2%~10%, 2%~10%, 2%~4%, 2%~6%, 2%~8%.
Preferably, in another embodiment of the present invention, bacteriophagic Bdellovibrio bacteria suspension and protective agent are molten in the step c
The mixed volume ratio of liquid is 1:1~1:2.
Preferably, in yet another embodiment of the present invention, the parameter that the step d is handled the lyophilized formulations is pre-
It is -30~-20 DEG C to freeze temperature, and the pre-freeze time is 2~5 hours, and freezing dry process temperature range is -15~37 DEG C, vacuum model
Enclose for 0.05 millibar~0.2 millibar, freeze-drying time is 24~48 hours.
Preferably, in another embodiment of the present invention, to the characters of the block lyophilized formulations in the step d
For：Loose block structure, water content is 1~5%, and survival rate is more than 85%.
Below in conjunction with the embodiment in the present invention, the technical scheme in the present invention is clearly and completely described.It is aobvious
So, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based on the reality in the present invention
Example is applied, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made all belongs to
In the scope of protection of the invention.
The production technology 1 of the bacteriophagic Bdellovibrio freeze-dried powder preparation of embodiment 1
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension.
Conventional culture methods：Take 50ml Bdellovibrio liquid (107Pfu/ml) with 50ml bacillus licheniformis liquid (108cfu/
Ml) mix, be inoculated in 20 liters of fermentation tanks, liquid amount is 10 liters, and temperature is 28 DEG C, and rotating speed is 150rpm, and throughput is 10L/L/
Min, ferments 3 days, obtains Bdellovibrio zymotic fluid
The culture of Bdellovibrio zymotic fluid is formulated：1% peptone, 0.3% beef extract, 0.5% sodium chloride, 0.3% dusty yeast.
After fermentation ends, 1 liter of bacillus subtilis bacterium solution (10 is added to zymotic fluid13Cfu/ml), it is ensured that bacteriophagic Bdellovibrio
It is with Bacillus subtilis number ratio：1:10.
B. the preparation and the preparation of lyophilized liquid of protection agent solution
It is to dissolve skimmed milk power, beta-schardinger dextrin, sea respectively using 10 liters of purified waters of sterilizing to protect agent solution process for preparation
Algae sugar, mannitol, asparatate so that its final mass concentration is respectively 2%, 2%, 2%, 2%, 2%.Protective agent is molten
Liquid and the bacteriophagic Bdellovibrio bacteria suspension of a technical process are according to 1：1 volume ratio is mixed, and 20 liters of bacteriophagic Bdellovibrios are made and treat lyophilized mixed
Close liquid；
C. the preparation of freeze dried preparation of bacteriophagic Bdellovibrio
Bacteriophagic Bdellovibrio mixed liquor to be freezed in technique b is put into Dong Fulong vacuum freeze dryers (LYO-2m2) in
Freezed, its pre-freezing temperature is -30 DEG C, the pre-freeze time is 2 hours, and vacuum is 0.2 millibar, wherein the temperature once distilled
For -15 DEG C, the time is 24 hours, and secondary sublimation temperature is 10 DEG C, and the time is 24 hours, and it is thin finally to obtain 800g lyophilized formulations
The block structure of pine, its water content is 5%, and Bdellovibrio survival rate is 95%
D. block lyophilized formulations are vacuumized repeatedly, gas flow is controlled by flowmeter using nitrogen cylinder, with
0.5L/min speed rushes nitrogen to the freeze-dried powder that vacuum packet is installed, untill packaging bag sticks out, and so inflation is vacuumized,
So that lyophilized formulations ultimately become powdered, final Bdellovibrio survival rate is 95%.
The production technology 2 of the bacteriophagic Bdellovibrio freeze-dried powder preparation of embodiment 2
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension.
Bacterium solution is obtained according to the following conventional culture methods of bacteriophagic Bdellovibrio
Conventional culture methods：Take 100ml Bdellovibrio liquid (107Pfu/ml) with 100ml bacillus licheniformis liquid (108cfu/
Ml) mix, be inoculated in 30 liters of fermentation tanks, liquid amount is 20 liters, and temperature is 28 DEG C, and rotating speed is 150rpm, and throughput is 20L/L/
Min, ferments 3 days, obtains Bdellovibrio zymotic fluid
The culture of Bdellovibrio zymotic fluid is formulated：1% peptone, 0.3% beef extract, 0.5% sodium chloride, 0.3% dusty yeast.
After fermentation ends, 1 liter of Bacillus licheniformis liquid (10 is added to zymotic fluid13Cfu/ml), it is ensured that bacteriophagic Bdellovibrio
It is with bacillus licheniformis quantitative proportion：1:100.
B. the preparation and the preparation of lyophilized liquid of protection agent solution
Protection agent solution process for preparation is to dissolve skimmed milk power, beta-schardinger dextrin, sea respectively using the purified water of 20 liters of sterilizings
Algae sugar, mannitol, asparatate so that its final mass concentration is respectively 5%, 5%, 5%, 5%, 5%.Protective agent is molten
Liquid and the bacteriophagic Bdellovibrio bacteria suspension of a technical process are according to 1：1 volume ratio is mixed, and 40 liters of bacteriophagic Bdellovibrios are made and treat lyophilized mixed
Close liquid；
C. the preparation of freeze dried preparation of bacteriophagic Bdellovibrio
Bacteriophagic Bdellovibrio mixed liquor to be freezed in technique b is put into Dong Fulong vacuum freeze dryers (LYO-2m2) in
Freezed, its pre-freezing temperature is -25 DEG C, the pre-freeze time is 4 hours, and vacuum is 0.2 millibar, wherein the temperature once distilled
For -5 DEG C, the time is 18 hours, and secondary sublimation temperature is 25 DEG C, and the time is 18 hours, and it is thin finally to obtain 1600g lyophilized formulations
The block structure of pine, its water content is 5%, and Bdellovibrio survival rate is 95%
D. block lyophilized formulations are vacuumized repeatedly, gas flow is controlled by flowmeter using nitrogen cylinder, with
0.5L/min speed rushes nitrogen to the freeze-dried powder that vacuum packet is installed, untill packaging bag sticks out, and so inflation is vacuumized,
So that lyophilized formulations ultimately become powdered；
E. block lyophilized formulations are vacuumized repeatedly, rushes inert gas so that lyophilized formulations ultimately become powder
Shape.
The production technology 3 of the bacteriophagic Bdellovibrio freeze-dried powder preparation of embodiment 3
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension.
Bacterium solution is obtained according to the conventional culture methods of bacteriophagic Bdellovibrio
Conventional culture methods：Take 50ml Bdellovibrio liquid (107Pfu/ml) with 50ml enterococcus faecalis bacterium solution (108cfu/ml)
Mixing, is inoculated in 10 liters of fermentation tanks, and liquid amount is 5 liters, and temperature is 28 DEG C, and rotating speed is 100rpm, and throughput is 5L/L/min, hair
Ferment 3 days, obtains Bdellovibrio zymotic fluid
The culture of Bdellovibrio zymotic fluid is formulated：1% peptone, 0.3% beef extract, 0.5% sodium chloride, 0.3% dusty yeast.
B. the preparation and the preparation of lyophilized liquid of protection agent solution
Protection agent solution process for preparation is to dissolve skimmed milk power, beta-schardinger dextrin, sea respectively using the purified water of 10 liters of sterilizings
Algae sugar, mannitol, asparatate so that its final mass concentration is respectively 10%, 10%, 10%, 10%, 10%.It will protect
Agent solution is protected with the bacteriophagic Bdellovibrio bacteria suspension of a technical process according to 1：2 volume ratios are mixed, and 15 liters of bacteriophagic Bdellovibrios are made and treat
Lyophilized mixed liquor；
C. the preparation of freeze dried preparation of bacteriophagic Bdellovibrio
Bacteriophagic Bdellovibrio mixed liquor to be freezed in technique b is put into Dong Fulong vacuum freeze dryers (LYO-2m2) in
Freezed, its pre-freezing temperature is -20 DEG C, the pre-freeze time is 5 hours, and vacuum is 0.1 millibar, wherein the temperature once distilled
For 0 DEG C, the time is 15 hours, and secondary sublimation temperature is 37 DEG C, and the time is 15 hours, and it is thin finally to obtain 1200g lyophilized formulations
The block structure of pine, its water content is 5%, and Bdellovibrio survival rate is 93%
D. block lyophilized formulations are vacuumized repeatedly, gas flow is controlled by flowmeter using nitrogen cylinder, with
0.5L/min speed rushes nitrogen to the freeze-dried powder that vacuum packet is installed, untill packaging bag sticks out, and so inflation is vacuumized,
So that lyophilized formulations ultimately become powdered；
E. block lyophilized formulations are vacuumized repeatedly, rushes inert gas so that lyophilized formulations ultimately become powder
Shape.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of production method of freeze dried preparation of bacteriophagic Bdellovibrio, comprises the following steps：
A. the acquisition of bacteriophagic Bdellovibrio bacteria suspension：Conventional culture methods according to bacteriophagic Bdellovibrio obtain bacterium solution, and host is without cause
The Gram-negative bacteria of characteristic of disease, or by harmful host separate after bacteriophagic Bdellovibrio bacteria suspension；
B. the preparation of agent solution is protected：The bacteriophagic Bdellovibrio bacteria suspension of agent solution and the step a will be protected according to 1：1 volume ratio
Example mixing, obtained bacteriophagic Bdellovibrio mixed liquor to be freezed；
C. the freeze-drying of mixed liquor to be freezed：
Bacteriophagic Bdellovibrio mixed liquor to be freezed is positioned in vacuum freeze dryer and carries out vacuum freeze drying, is bitten
Bacterium Bdellovibrio lyophilized formulations；
D. block lyophilized formulations are vacuumized repeatedly, rushes inert gas so that preparation ultimately becomes powdered；
E. above-mentioned bacteriophagic Bdellovibrio freeze-dried powder preparation is sealed under vacuum or under conditions of filling inert gas
Packaging, is made bacteriophagic Bdellovibrio freeze-dried powder preparation finished product.
2. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 1, it is characterised in that the step a
No pathogenicity host is：Bacillus subtilis, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, bulgarian milk bar
The newborn bar of bacterium, Pediococcus acidilactici, streptococcus lactis, VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactic acid
The one or more of bacterium, Lactobacillus plantarum or Pediococcus pentosaceus.
3. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 1, it is characterised in that the step a
Bacteriophagic Bdellovibrio bacteria suspension be the Gram-negative bacteria containing no pathogenicity bacteriophagic Bdellovibrio bacteria suspension.
4. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 3, it is characterised in that the nothing is caused a disease
Property derived from gram-negative bacteria be host in itself or by manually adding acquisitions, the leather orchid of final bacteriophagic Bdellovibrio and no pathogenicity
Family name's negative bacterium quantitative proportion is：1:10~1：100.
5. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 3, it is characterised in that described without cause
The Gram-negative bacteria of characteristic of disease is bacillus subtilis, bafillus natto, bifidobacterium bifidum, enterococcus faecalis, Bulgaria
Lactobacillus, Pediococcus acidilactici, streptococcus lactis, VREF, bacillus licheniformis, lactobacillus acidophilus, Lactobacillus casei, lactic acid
Lactobacillus, Lactobacillus plantarum or the one or more of Pediococcus pentosaceus.
6. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 1, it is characterised in that the step b
Protection agent solution compound method be to dissolve skimmed milk power, beta-schardinger dextrin, trehalose, sweet dew respectively using the purified water of sterilizing
Alcohol, asparatate so that its final mass concentration is respectively 2%~10%, 2%~10%, 2%~4%, 2%~6%,
2%~8%.
7. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 1, it is characterised in that the step c
The mixed volume ratio of middle bacteriophagic Bdellovibrio bacteria suspension and protection agent solution is 1:1~1:2.
8. bacteriophagic Bdellovibrio freeze-dried powder preparation production method according to claim 1, it is characterised in that d pairs of the step
The parameter of the lyophilized formulations processing is that pre-freezing temperature is -30~-20 DEG C, and the pre-freeze time is 2~5 hours, freezing dry process
Temperature range is -15~37 DEG C, and vacuum range is 0.05 millibar~0.2 millibar, and freeze-drying time is 24~48 hours.
9. the production method of bacteriophagic Bdellovibrio freeze-dried powder preparation according to claim 1, it is characterised in that the step d
In be to the characters of the block lyophilized formulations：Loose block structure, water content is 1~5%, and survival rate is more than 85%.
10. the bacteriophagic Bdellovibrio freeze-dried powder preparation that the method according to claim 1~9 any one is obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710450413.3A CN107213171A (en) | 2017-06-15 | 2017-06-15 | A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710450413.3A CN107213171A (en) | 2017-06-15 | 2017-06-15 | A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107213171A true CN107213171A (en) | 2017-09-29 |
Family
ID=59949552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710450413.3A Pending CN107213171A (en) | 2017-06-15 | 2017-06-15 | A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213171A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110169982A (en) * | 2019-06-06 | 2019-08-27 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing batrachia torticollis disease |
| CN110179833A (en) * | 2019-06-06 | 2019-08-30 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing grouper ulcer |
| CN110215466A (en) * | 2019-06-06 | 2019-09-10 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing common eel bacteriosis |
| CN112913966A (en) * | 2021-03-30 | 2021-06-08 | 广东国联海洋生物科技研究院有限公司 | Method for producing freeze-dried preparation of sea chain algae |
| CN114181913A (en) * | 2021-12-14 | 2022-03-15 | 厦门昶科生物工程有限公司 | Phage freeze-dried powder preparation and production method thereof |
| CN115786204A (en) * | 2022-12-01 | 2023-03-14 | 中国水产科学研究院黄海水产研究所 | Vacuum freeze-drying protective agent suitable for vibrios and freeze-drying method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1320421A (en) * | 2000-04-25 | 2001-11-07 | 南京威力克生物有限公司 | Freeze dried preparation of bacteriophagic Bdellovibrio and its preparing process |
| WO2006079911A1 (en) * | 2005-01-26 | 2006-08-03 | Omya Development Ag | Method for controlling microbial contamination, mineral suspensions obtained and uses thereof |
| CN101948784A (en) * | 2010-08-31 | 2011-01-19 | 华南理工大学 | Bdellovibrio bacteriovorus preparation and fermentation method and application thereof |
-
2017
- 2017-06-15 CN CN201710450413.3A patent/CN107213171A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1320421A (en) * | 2000-04-25 | 2001-11-07 | 南京威力克生物有限公司 | Freeze dried preparation of bacteriophagic Bdellovibrio and its preparing process |
| WO2006079911A1 (en) * | 2005-01-26 | 2006-08-03 | Omya Development Ag | Method for controlling microbial contamination, mineral suspensions obtained and uses thereof |
| CN101948784A (en) * | 2010-08-31 | 2011-01-19 | 华南理工大学 | Bdellovibrio bacteriovorus preparation and fermentation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 黄文等: "噬菌蛭弧菌Bd-9五种保藏方法的比较研究", 《大连水产学院学报》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110169982A (en) * | 2019-06-06 | 2019-08-27 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing batrachia torticollis disease |
| CN110179833A (en) * | 2019-06-06 | 2019-08-30 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing grouper ulcer |
| CN110215466A (en) * | 2019-06-06 | 2019-09-10 | 厦门惠盈动物科技有限公司 | A kind of phage bdellovibro preparation and its application for preventing common eel bacteriosis |
| CN112913966A (en) * | 2021-03-30 | 2021-06-08 | 广东国联海洋生物科技研究院有限公司 | Method for producing freeze-dried preparation of sea chain algae |
| CN114181913A (en) * | 2021-12-14 | 2022-03-15 | 厦门昶科生物工程有限公司 | Phage freeze-dried powder preparation and production method thereof |
| CN115786204A (en) * | 2022-12-01 | 2023-03-14 | 中国水产科学研究院黄海水产研究所 | Vacuum freeze-drying protective agent suitable for vibrios and freeze-drying method |
| CN115786204B (en) * | 2022-12-01 | 2023-08-15 | 中国水产科学研究院黄海水产研究所 | Vacuum freeze-drying protective agent and freeze-drying method suitable for vibrio |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107213171A (en) | A kind of preparation method of bacteriophagic Bdellovibrio freeze-dried powder | |
| Dieuleveux et al. | Antimicrobial spectrum and target site of D-3-phenyllactic acid | |
| Gaggia et al. | The role of protective and probiotic cultures in food and feed and their impact in food safety | |
| Ananou et al. | Control of Listeria monocytogenes in model sausages by enterocin AS-48 | |
| Sabouri et al. | A minireview on the in vitro and in vivo experiments with anti-Escherichia coli O157: H7 phages as potential biocontrol and phage therapy agents | |
| Jofré et al. | Impact of different cryoprotectants on the survival of freeze-dried Lactobacillus rhamnosus and Lactobacillus casei/paracasei during long-term storage | |
| ES2522716B1 (en) | Lactobacillus plantarum strain for bacterial fire control | |
| ES2428513T3 (en) | Biofungicidal composition for the control of phytopathogenic fungi | |
| KR101372200B1 (en) | Lactobacillus plantarum SY99 and Use Thereof | |
| CN113170842B (en) | Composite microecological preparation for preventing and treating necrotic enteritis of poultry and application thereof | |
| US8821855B2 (en) | Methods for isolating phage and for controlling microorganism populations with the phage | |
| Petsong et al. | Evaluation of storage conditions and efficiency of a novel microencapsulated Salmonella phage cocktail for controlling S. enteritidis and S. typhimurium in-vitro and in fresh foods | |
| US5006347A (en) | Process for retarding bacterial growth in cheese | |
| LT6270B (en) | Probiotic fermented feed additives | |
| Wójcicki et al. | The concept of using bacteriophages to improve the microbiological quality of minimally processed foods | |
| KR101818859B1 (en) | Pseudomonas azotoformans strain KACC 92125P and composition for comprising the same | |
| Hadad Khodaparast et al. | Effect of essential oil and extract of Ziziphora clinopodioides on yoghurt starter culture activity | |
| KR100585391B1 (en) | Acid tolerant probiotic Lactobacillus plantarum Probio-38 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus | |
| KR20220071772A (en) | Livestock production and processing method using sterilization by lactobacillaceae | |
| KR20120118570A (en) | Lactococcus lactis et45 and use thereof | |
| CN104531561A (en) | (Lactobacillus planetarium subsp. plantarum)Zhang-LL bacteriocin and Nisin composite bacteriostatic agent and its use in chilled meat | |
| Borges et al. | Characterization of a bacteriocin of Pediococcus pentosaceus SB83 and its potential for vaginal application | |
| Gisela et al. | Enhacement of the viability of Lactobacillus plantarum during the preservation and storage process based on the response surface methodology | |
| Saucier et al. | Immobilised-cell technology and meat processing | |
| CN114736834B (en) | Bacillus pumilus TS1 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170929 |
|
| RJ01 | Rejection of invention patent application after publication |